rethinkTHC Search
Menu
Study breakdown

Primates can learn to distinguish between cannabinoid receptor activation and blockade

Animal StudyPreliminary evidence
The takeaway

Squirrel monkeys successfully discriminated the cannabinoid antagonist rimonabant from vehicle, providing a new tool for studying how cannabinoid receptor blockade feels subjectively.

Behavioral pharmacologists, cannabinoid researchers, and drug development scientists.

THC blocked the rimonabant discrimination, confirming CB1 mechanism

What the researchers found

Squirrel monkeys were trained to discriminate rimonabant (a CB1 antagonist/inverse agonist) from vehicle in a drug discrimination paradigm. The discrimination was dose-dependent and could be blocked by THC, confirming it was mediated through CB1 receptors.

Why it matters

Drug discrimination procedures reveal how substances "feel" to animals, providing insight into subjective effects. Establishing that cannabinoid blockade produces discriminable effects helps researchers study the endocannabinoid system and potential therapeutic applications of antagonists.

The numbers in context

Squirrel monkeys discriminated rimonabant from vehicle in a dose-dependent manner; THC blocked the rimonabant discrimination.

How the study worked

Drug discrimination study in squirrel monkeys using a two-lever food-reinforced operant procedure. Animals were trained to discriminate rimonabant from vehicle across multiple dose levels.

What this study cannot tell us

Animal study with a small number of primates; subjective effects in monkeys may not directly translate to human experience. Rimonabant is no longer marketed for clinical use.

How to read the evidence

Preliminary: animal behavioral pharmacology study with small sample size.

When this study was published

Published 2016.

The bigger picture

Understanding how cannabinoid receptor blockade is perceived is relevant for developing potential treatments. Rimonabant was once marketed for obesity but withdrawn due to psychiatric side effects. Better understanding its subjective effects could inform safer drug development.

Questions still open

  • Could newer, more selective CB1 antagonists avoid the psychiatric side effects seen with rimonabant while retaining therapeutic benefits?

Common questions

What is drug discrimination?
A behavioral method where animals learn to press different levers depending on whether they received a drug or placebo. It reveals whether a substance produces distinct internal cues or "feelings."
What happened to rimonabant?
Rimonabant was approved in Europe for obesity treatment but was withdrawn in 2008 due to increased risk of depression and suicidal ideation.

Read the original research

Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates.

The Journal of pharmacology and experimental therapeutics, 372(1), 119-127

Citation

Kangas, Brian D; Zakarian, Ani S; Vemuri, Kiran; Alapafuja, Shakiru O; Jiang, Shan; Nikas, Spyros P; Makriyannis, Alexandros; Bergman, Jack. (2020). Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates.. The Journal of pharmacology and experimental therapeutics, 372(1), 119-127. https://doi.org/10.1124/jpet.119.261818

Explore the wider topic